SureTrader
Home > Boards > US Listed > Medical - Drugs >

TrovaGene, Inc. (TROV)

TROV RSS Feed
Add TROV Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 1/6/2018 5:31:02 PM - Followers: 53 - Board type: Free - Posts Today: 0

Trovagene logoTrovagene, Inc. 
11055 Flintkote Ave., Suite B
San Diego, CA 92121
USA
 
Tel: USA [+1] 858 217 4838
Fax: USA [+1] 858 217 4768 
E-mail:  service@trovagene.com
http://trovagene.com/
 
TrovaGene, Inc. is a publicly traded company molecular diagnostics company, with headquarters in San Diego, California. We are dedicated to the development and commercialization of unique, proprietary, molecular in-vitro diagnostics technologies. 
The company's founding scientists were the first to report that cell free fragments of DNA from normal cell death that circulate in the blood can cross the kidney barrier and be detected in urine. 
These cell-free nucleic fragments that pass through the kidney ("transrenal" or Tr-DNA/RNA) can be used as genetic markers of disease. The company believes that this transrenal technology will open significant new markets in the molecular diagnostics field and lead to improvements in the area of personalized medicine.

TroveGene, Inc. news

Attention: Gabriele Cerrone, Director of Trovagene
 
Gabriele Cerrone, Founder and Chairman of FermaVir Pharmaceuticals.
FermaVir Pharmaceuticals was bought out by Inhibitex (INHX) in 2007 and Gabriele Cerrone was appointed a Director of the acquiring company.
Bristol-Myers Squibb offered $2.5 Billion to acquire Inhibitex.

Bristol-Myers Squibb to Acquire Inhibitex

InhibitexReleased: 01/07/12 09:13 PM EST
Bristol-Myers Squibb Company (NYSE:BMY) and Inhibitex, Inc. (Nasdaq:INHX) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger. The transaction, with an aggregate purchase price of approximately $2.5 billion, has been approved by the boards of directors of both companies. The board of directors of Inhibitex has agreed to recommend that Inhibitex's shareholders tender their shares in the tender offer. In addition, shareholders with beneficial ownership of approximately 17% of Inhibitex's common stock have entered into agreements with Bristol-Myers Squibb to support the transaction and to tender their shares in the tender offer.

Gabriele Cerrone holds an 11.4% interest in Trovagene.

Highlights:

Trovagene Closes Acquisition of CLIA Laboratory Assets
 
SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, today announced that it has closed its acquisition of MultiGEN Diagnostics, Inc.'s clinical laboratory assets.  Trovagene previously announced the execution of the Asset Acquisition Agreement on January 6, 2012.

Antonius Schuh, Ph.D. Joins TrovaGene, Inc. As Chief Executive Officer

SAN DIEGO--(BUSINESS WIRE)-- TrovaGene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, has announced that Antonius Schuh, Ph.D. has been named Chief Executive Officer. Dr. Schuh previously served as Chairman and Chief Executive Officer of Sorrento Therapeutics, Inc. (Pink Sheets: SRNE.PK), a biotechnology company he co-founded based on a proprietary platform to generate very large fully human antibody libraries. Sorrento Therapeutics merged in 2009 with a public company supported by Phillip Frost and the Frost Group.
 
Dr. Schuh also served as the founding CEO of AviaraDx, Inc., a leading molecular diagnostic innovator in oncology. In 2008, Dr. Schuh led the sale of AviaraDx to bioMerieux, which continues to operate AviaraDx under the name bioTheranostics. Before AviaraDx, Dr. Schuh served as CEO of Arcturus Bioscience, Inc., where he led the sale of Arcturus' life science business to Molecular Devices, Inc. From 2000 to 2005, Dr. Schuh served as the President and Chief Executive Officer of Sequenom, Inc. (Nasdaq: SQNM - News). He had joined Sequenom in 1996 as Managing Dierctor of its European operations, and led during his tenure, amongst others, the commercial launch of the MassARRA® system and numerous business development and corporate acquisition transactions. Dr. Schuh holds a degree in pharmaceutics and earned his Ph.D. in medicinal chemistry from the University of Bonn, Germany.
 
"We are pleased and fortunate that Dr. Schuh joins us to lead the transition of TrovaGene from a research stage organization to a commercial enterprise," states Dr. Thomas Adams, TrovaGene's Chairman. "The company has made significant efforts to establish the utility of trans-renal nucleic acids in urine as a diagnostic sample in clinical fields as diverse as detection of minimal residual disease in oncology, infectious disease, transplant medicine and prenatal monitoring. Dr. Schuh has a proven track record of building companies and creating value for shareholders. I look forward to working with him."
 
"I have observed TrovaGene closely over the past years, as I have been intrigued by the attractive opportunities the Company's proprietary trans-renal technologies offer, and I am confident that we can introduce novel diagnostic modalities with significant clinical utility based on this platform," states Dr. Schuh.

TROV executives
TROV board


Targeted $40 Billion market space:
TROV market space



SureTrader
TROV
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TROV News: Amended Statement of Ownership (sc 13g/a) 01/09/2018 01:21:18 PM
TROV News: Current Report Filing (8-k) 01/08/2018 06:10:29 AM
TROV News: Statement of Changes in Beneficial Ownership (4) 01/04/2018 05:19:56 PM
TROV News: Statement of Changes in Beneficial Ownership (4) 01/04/2018 05:18:39 PM
TROV News: Statement of Changes in Beneficial Ownership (4) 01/04/2018 05:18:14 PM
PostSubject
#1000   Not bad at all...more so given the overall Full Contact Yoga 01/06/18 05:31:02 PM
#999   Love the action today with volume and steady stockmule 01/05/18 06:07:20 PM
#998   Yep...not really fully tradable, they still have to Full Contact Yoga 01/05/18 12:12:48 PM
#997   I don't believe these are sales but conversion stockmule 01/05/18 09:39:25 AM
#996   $10k worth. Not much of a party zoomboom 01/04/18 08:57:38 PM
#995   Its a Form 4 Party Filterthenoise 01/04/18 07:39:52 PM
#994   Gap at .42 gonna close soon then it bigblue72 01/04/18 12:50:01 PM
#993   Back over $1 by Feb briphelps 01/04/18 12:44:31 PM
#992   Moon is coming over the next couple months. Filterthenoise 01/04/18 12:34:10 PM
#991   Moon BallsD33pTrader 01/04/18 12:00:58 PM
#990   Yes it is stockmule, I'm very glad that DFRANK1970 01/04/18 11:59:57 AM
#989   Looks like some quiet buying taking place. I bigblue72 01/04/18 10:07:41 AM
#988   That entry is looking very very good right stockmule 01/04/18 09:33:32 AM
#987   Need to bust thru .31 here, then its bigblue72 01/03/18 12:55:52 PM
#986   They have time though, no real hurry unless Full Contact Yoga 01/02/18 01:23:03 AM
#985   I don't care about buyers reporting; the company beachboy3 01/01/18 10:14:57 AM
#984   It wouldn't be the first time an offering beachboy3 01/01/18 09:13:57 AM
#983   This offering was for insiders. Public just Filterthenoise 12/29/17 01:40:52 PM
#982   The offering closes to future investors on that Full Contact Yoga 12/29/17 01:12:23 PM
#981   That filing confuses me because it states "will" beachboy3 12/29/17 12:47:51 PM
#980   The offering is most likely done but the Filterthenoise 12/29/17 11:03:24 AM
#979   Quite possible that it has to some extent. Full Contact Yoga 12/29/17 10:54:33 AM
#978   The stock/warrant sale was supposed to close by beachboy3 12/29/17 10:46:20 AM
#977   All these predictions are nice so I will stockmule 12/29/17 09:32:16 AM
#976   Nice post. The story always needs to Filterthenoise 12/28/17 09:12:15 PM
#975   Could be, worth watching. Lost 88% on the Full Contact Yoga 12/28/17 05:04:06 PM
#974   Lol $385 a share GotDrys 12/28/17 05:02:26 PM
#973   There is...... bigblue72 12/28/17 04:55:48 PM
#972   wish there was a way to block people... trader1up 12/28/17 04:45:18 PM
#971   Agree with you here. That is ridiculous. Filterthenoise 12/28/17 04:32:38 PM
#970   Ridiculous... Full Contact Yoga 12/28/17 04:12:09 PM
#969   We gonna fill that gap at .40 soon. bigblue72 12/28/17 03:43:08 PM
#968   At least $100 a share!!! By February GotDrys 12/28/17 11:16:41 AM
#967   Load up now while the gett'n is good.... https://stockflare.com/stock/TROV.O herbied47 12/28/17 11:14:15 AM
#966   $100/share in 1 month; $500/share by April. beachboy3 12/27/17 03:30:12 PM
#963   Way oversold! Time to start filling that gap herbied47 12/27/17 10:48:05 AM
#962   I agree. briphelps 12/22/17 08:56:07 AM
#961   I know predictions are always hilarious, take them Filterthenoise 12/21/17 02:18:21 PM
#960   .27? looks like this should move a bit.. Tdash 12/21/17 01:59:41 PM
#959   Hilarious...based on what? Full Contact Yoga 12/21/17 09:32:02 AM
#958   This may not be your average bounce. $5 Filterthenoise 12/20/17 09:54:28 PM
#957   It should start to go up to .30 stockmule 12/19/17 11:01:57 AM
#956   Looks like there is a large gap to bigblue72 12/16/17 04:07:41 PM
#955   Nice price we should do well in the stockmule 12/15/17 07:28:31 PM
#954   * * $TROV Video Chart 12-15-17 * * ClayTrader 12/15/17 05:13:46 PM
#953   stockmule, 100% agree with you, I'm in @$0.249. DFRANK1970 12/15/17 04:27:08 PM
#952   I expect a bounce so not going to stockmule 12/15/17 10:40:16 AM
#951   Massive turd failure... Full Contact Yoga 12/15/17 10:08:55 AM
#950   I am a buyer down here, price is stockmule 12/15/17 09:51:36 AM
#949   I hope so, just bought 40,000 shares here briphelps 12/14/17 02:11:11 PM
PostSubject